U.S. markets close in 2 hours 33 minutes
  • S&P 500

    4,165.60
    +40.94 (+0.99%)
     
  • Dow 30

    33,998.14
    +267.25 (+0.79%)
     
  • Nasdaq

    14,015.25
    +157.41 (+1.14%)
     
  • Russell 2000

    2,242.91
    -4.80 (-0.21%)
     
  • Crude Oil

    63.31
    +0.16 (+0.25%)
     
  • Gold

    1,767.10
    +30.80 (+1.77%)
     
  • Silver

    25.99
    +0.47 (+1.83%)
     
  • EUR/USD

    1.1963
    -0.0020 (-0.17%)
     
  • 10-Yr Bond

    1.5440
    -0.0940 (-5.74%)
     
  • GBP/USD

    1.3778
    -0.0002 (-0.02%)
     
  • USD/JPY

    108.7400
    -0.1870 (-0.17%)
     
  • BTC-USD

    62,752.46
    -665.26 (-1.05%)
     
  • CMC Crypto 200

    1,375.85
    -5.10 (-0.37%)
     
  • FTSE 100

    6,983.50
    +43.92 (+0.63%)
     
  • Nikkei 225

    29,642.69
    +21.70 (+0.07%)
     

Announcing: ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Increased An Energizing 191% In The Last Five Years

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if you buy shares in a high quality company at the right price, you can gain well over 100%. Long term ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shareholders would be well aware of this, since the stock is up 191% in five years.

See our latest analysis for ACADIA Pharmaceuticals

Because ACADIA Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

In the last 5 years ACADIA Pharmaceuticals saw its revenue grow at 56% per year. That's well above most pre-profit companies. Meanwhile, its share price performance certainly reflects the strong growth, given the share price grew at 24% per year, compound, during the period. This suggests the market has well and truly recognized the progress the business has made. To our minds that makes ACADIA Pharmaceuticals worth investigating - it may have its best days ahead.

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

earnings-and-revenue-growth
earnings-and-revenue-growth

ACADIA Pharmaceuticals is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. You can see what analysts are predicting for ACADIA Pharmaceuticals in this interactive graph of future profit estimates.

A Different Perspective

ACADIA Pharmaceuticals shareholders are up 19% for the year. Unfortunately this falls short of the market return. If we look back over five years, the returns are even better, coming in at 24% per year for five years. It may well be that this is a business worth popping on the watching, given the continuing positive reception, over time, from the market. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 2 warning signs for ACADIA Pharmaceuticals that you should be aware of.

Of course ACADIA Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.